Ann: OncoSil receives Swiss regulatory approval, page-37

The main news that will move the SP are FDA and EU sales. Both could and should arrive in the next week or two.

II agree there is some volume movement, and that the SP momentum has risen. I also agree that any accumulation is not resulting in a more significant SP increase because imo the last capital raise sucked all demand. But I was very surprised with the Chairman's last share purchase - that's not a token statement of support, that's an move to make money.

The main problem with this company is not the technology but the CEO. I note that Nigel Lange's appointment drove significant confidence earlier in the year. The CEO has been there 6 years, and frankly I think he's a bit short of the mark.

A China/Japan deal or a US partnership would help a lot. Telix has already made a deal with China Grand, and they have been around only for 2 years.

If the EU sales don't eventuate, after he clearly gave guidance they definitely would, then he should be replaced.

So, in an odd way it's win-win: get the EU sales SP rises, don;t get them he goes and the SP will also rise.